GlassScriptPhysician profile
Sarah M Abbassi
NPI 1306209671
$1,510.07
in general payments reported to CMS, 2019-2025
20 companies · $479 in 2025
The $479 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.40 · 2021: $63.31 · 2022: $598 · 2023: $182 · 2024: $175 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $738 · Education: $97.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $737.59 |
| Education | $97.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $364.10 | 2021-2025 | |
| Optinose US, INC. | $141.85 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $129.46 | 2022-2025 | Dupixent |
| Csl Behring | $121.71 | 2022-2025 | Andembry, Haegarda |
| Astrazeneca Pharmaceuticals LP | $121.42 | 2021-2024 | Tezspire, Fasenra |
| Sanofi-Aventis U.S. LLC | $97.99 | 2025 | |
| Amgen INC. | $68.76 | 2023-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $67.54 | 2022-2025 | Orladeyo |
| Glaxosmithkline, LLC. | $66.12 | 2020-2022 | |
| Kaleo, INC. | $63.55 | 2022-2024 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $46.64 | 2022-2023 | |
| Grifols USA, LLC | $43.21 | 2022 | |
| Incyte Corporation | $41.77 | 2021-2022 | |
| Galderma Laboratories, L.P. | $33.04 | 2025 | Nemluvio |
| Cycle Pharmaceuticals INC | $21.24 | 2025 | Sajazir |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $18.10 | 2024 | |
| Ionis Pharmaceuticals, INC. | $17.16 | 2025 | Dawnzera |
| Takeda Pharmaceuticals U.S.A., INC. | $16.81 | 2022 | |
| Aimmune Therapeutics, INC. | $15.95 | 2022 | |
| Blueprint Medicines Corporation | $13.65 | 2024 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Abbassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.